Anavex Life Sciences has announced promising findings from their Phase 2b/3 trial of blarcamesine
(ANAVEX2-73) for the treatment of early Alzheimer’s disease. The study showed
significant reductions in amyloid-ß biomarkers and a notable slowing of brain
atrophy, signaling a potential breakthrough in Alzheimer’s treatment. 

The multicenter trial enrolled 508 participants who were randomly assigned to receive either
blarcamesine or a placebo over 48 weeks. Researchers utilized the Alzheimer’s
Disease Assessment Scale-Cognitive (ADAS-Cog) and the Alzheimer’s Disease
Cooperative Study-Activities of Daily Living (ADCS-ADL) subscales to evaluate
cognitive and functional changes. 

Notably, the blarcamesine group exhibited a statistically significant reduction in amyloid-ß
levels in plasma, with an improved plasma Aβ42/40 ratio. Brain MRI scans also
revealed a significant decrease in brain volume loss compared to the placebo
group. Such outcomes suggest that blarcamesine may help slow cognitive decline
and neurodegeneration in early-stage Alzheimer’s patients. 

Dr. Marwan Noel Sabbagh, professor of neurology and chairman of the Scientific Advisory Board
at Anavex Life Sciences, highlighted the potential benefits of blarcamesine,
emphasizing its oral administration and excellent safety profile. The
convenience of an oral treatment could make a substantial difference for
patients and caregivers alike. 

However, the study did report some adverse events, the most common being dizziness, which was
generally mild to moderate in severity. Despite this, the overall safety
profile of blarcamesine remains favorable, making it a compelling candidate for
further development. 

Christopher U Missling, PhD, CEO of Anavex Life Sciences, expressed gratitude to all participants and
researchers involved in the study. He underscored the company’s commitment to
advancing blarcamesine as a convenient and effective oral treatment option for Alzheimer’s disease. 

The trial results provide a solid foundation for the future development of blarcamesine, offering
hope for millions affected by Alzheimer’s disease. 

In summary, Anavex continues to make strides in Alzheimer’s research. Their investigational
agent, blarcamesine, shows significant potential for changing the landscape of
Alzheimer’s treatment. 

Refer to this article for additional information. 

Learn more about Anavex on https://www.nasdaq.com/market-activity/stocks/avxl